| 徐理倩,韩志刚,张亚丽,吴昊,高凯,黎庆梅,徐慧芳,蔡衍珊,夏云.广州市2008-2015年未接受抗病毒治疗的注射吸毒人群HIV-1感染者耐药分析[J].中华流行病学杂志,2019,40(2):196-201 |
| 广州市2008-2015年未接受抗病毒治疗的注射吸毒人群HIV-1感染者耐药分析 |
| Prevalence of antiretroviral drug resistance in treatment-naive injecting drug users infected with HIV-1 in Guangzhou, 2008-2015 |
| 收稿日期:2018-07-25 出版日期:2019-01-31 |
| DOI：10.3760/cma.j.issn.0254-6450.2019.02.014 |
| 中文关键词: 艾滋病病毒 注射吸毒人群 耐药 |
| 英文关键词: HIV Injecting drug user Drug resistance |
| 基金项目:广州市科技计划项目（201707010184） |
|
| 摘要点击次数: 4425 |
| 全文下载次数: 1594 |
| 中文摘要: |
| 目的 了解广州市未接受抗病毒治疗的注射吸毒人群（IDU）HIV-1感染者耐药株流行情况。方法 收集2008-2015年新确证HIV-1抗体阳性、现住址为广州市、传播途径为注射吸毒、确证时未接受抗病毒治疗的IDU HIV-1感染者的血清样本，提取HIV-1 RNA，采用巢式PCR法扩增pol区蛋白酶（PR）基因全序列与反转录酶（RT）基因部分序列并测序后，提交到美国斯坦福大学HIV耐药数据库做耐药分析。结果 518例HIV感染者中，有407例（78.57%）血清样本成功获得pol区基因片段。年龄18~64（37.44±8.14）岁，男性占89.68%（365/407），汉族占89.93%（366/407），未婚者占55.28%（225/407），文化程度以初中及以下为主（83.78%，341/407）。HIV-1亚型以CRF07_BC为主（47.18%，192/407），CRF01_AE占23.83%（97/407）和CRF08_BC占22.85%（93/407），其他亚型占6.14%（25/407）。总耐药率为3.44%（14/407），蛋白酶抑制剂耐药率为1.47%（6/407），核苷类反转录酶抑制剂耐药率为0.25%（1/407），非核苷类反转录酶抑制剂耐药率为1.72%（7/407）。突变发生率为12.29%（50/407），蛋白酶区和核苷类反转录酶区未检出主要耐药突变，非核苷类反转录酶区中V179E突变率更高的是其他亚型和CRF07_BC亚型，其他亚型中的CRF55_01B亚型8例全部发生此突变；E138A突变率最高的是CRF08_BC亚型，为3.23%。有2例病例对NNRTIs的4种药物全都耐药。结论 2008-2015年广州市未接受抗病毒治疗的IDU HIV-1感染者的耐药率处于较低水平，大多数IDU HIV-1感染者对现有抗病毒治疗药物敏感。应加强IDU HIV-1感染者的耐药监测，控制耐药性毒株多重、交叉耐药的流行。 |
| 英文摘要: |
| Objective To understand the prevalence of drug resistance in treatment-naive injecting drug users (IDUs) infected with HIV-1 in Guangzhou. Methods HIV-1 RNA were extracted from the serum specimens of the newly confirmed HIV-1 positive IDUs living in Guangzhou, being infected through injecting drug use and receiving no antiretroviral therapy at the time of confirmation during 2008-2015. Full sequence of pol protease (PR) gene and partial sequence of reverse transcriptase (RT) gene were amplified by nested reverse transcription polymerase chain reaction (nested-PCR) and sequenced. After that, data were submitted to the HIV resistance database of Stanford University for drug resistance analysis. Results Among the 518 HIV-1 infected IDUs, HIV-1 pol gene segments were successfully obtained from the serum samples of 407 HIV-1 infected IDUs (78.57%) aged 18-64 (37.44±8.14) years. Among them, males accounted for 89.68% (365/407), those of Han ethnic group accounted for 89.93% (366/407), the unmarried accounted for 55.28% (225/407), and those with education level of junior high school or below accounted for 83.78% (341/407). The distribution of subtypes was predominated by CRF07_BC (47.18%, 192/407), followed by CRF01_AE (23.83%, 97/407), CRF08_BC (22.85%, 93/407), and other subtypes (6.14%, 25/407). The overall prevalence of drug resistance was 3.44% (14/407). The prevalence of drug resistance to protease inhibitors, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors were 1.47%(6/407), 0.25% (1/407) and 1.72% (7/407) respectively. The mutation rate was 12.29% (50/407). No major drug resistance mutation was detected in protease and nucleoside reverse transcriptase regions. Higher rate of V179E mutation in the non-nucleoside reverse transcriptase region was detected in other subtypes and subtype CRF07_BC. Mutation seemed to have occurred in all 8 cases of subtype CRF55_01B in other subtypes. The highest mutation rate of E138A was detected in subtype CRF08_BC (3.23%). Two cases were resistant to all four drugs of NNRTIs. Conclusions The prevalence of drug resistance in treatment-naive HIV-1 positive IDUs remained at a relatively low level during 2008-2015, in Guangzhou. Most infections were sensitive to existing antiviral drugs. However, drug resistance surveillance in IDUs infected with HIV should be strengthened to prevent the prevalence of multi-drug resistance and cross drug resistance. |
|
查看全文
Html全文
查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
